Announcement on Change of Sponsor Representative for Continuous Supervision
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Change of Sponsor Representative for Continuous Supervision
Filed with SSE · · 4 pages · Chinese
On 6ix: 6ix.com/news/announcement-on-change-of-sponsor-representative-for-continuous-supervision-158
Release
Dizal (Jiangsu) Pharmaceutical Co. Ltd. on 6ix
Earlier from Dizal (Jiangsu) Pharmaceutical
- Announcement on Participation in the "Dialogue on Growth" 2025 and Q1 2026 Collective Performance Briefing
- Report for Q1 2026
- Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
- Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026
- Announcement on Resolutions of the 2025 Annual General Meeting
Later from Dizal (Jiangsu) Pharmaceutical
- Announcement on Voluntary Disclosure of Study Results of the Hematological Tumor Products, Golidocitinib Birelentinib, Being Selected To Present at the 2026 Annual Meeting of the European Hematology Association (EHA)
- Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Sunvozertinib as First-Line Monotherapy for EGFR Exon20ins Non-Small Cell Lung Cancer by the National Medical Products Administration and Its Inclusion in Priority Review
- Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
- Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
- Announcement on Voluntary Disclosure of Multiple Latest Research Advances in Lung Cancer at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Follow Dizal (Jiangsu) Pharmaceutical into a list and get an email when it puts out news.
Follow Dizal (Jiangsu) Pharmaceutical